7,631 to 7,640 of 8,021 Results
May 26, 2020 -
A Short Peptide Hydrogel with High Stiffness Induced by 310‐Helices to β‐Sheet Transition in Water
Unknown - 7.3 KB -
MD5: 0df4260da6c8c1b5c8143088a3b92966
|
May 26, 2020 -
A Short Peptide Hydrogel with High Stiffness Induced by 310‐Helices to β‐Sheet Transition in Water
Unknown - 200.0 KB -
MD5: ab4020e76480225e16765862358c89d5
|
May 26, 2020 -
A Short Peptide Hydrogel with High Stiffness Induced by 310‐Helices to β‐Sheet Transition in Water
Unknown - 198.5 KB -
MD5: 68fe4a9dcd38e2fd68e7ac53a91b7994
|
May 26, 2020 -
A Short Peptide Hydrogel with High Stiffness Induced by 310‐Helices to β‐Sheet Transition in Water
Unknown - 198.8 KB -
MD5: 9903b9121e51e242f2eb0ef8a5b2ce7e
|
May 26, 2020 -
A Short Peptide Hydrogel with High Stiffness Induced by 310‐Helices to β‐Sheet Transition in Water
Unknown - 198.8 KB -
MD5: 3aa4063bbd6b1483f3bb19231579f43a
|
May 26, 2020 -
A Short Peptide Hydrogel with High Stiffness Induced by 310‐Helices to β‐Sheet Transition in Water
Tabular Data - 330.8 KB - 95 Variables, 608 Observations - UNF:6:fqb27Au0CDxbI40IDbnSaA==
Raw_CD_data_and_processing |
May 26, 2020 -
A Short Peptide Hydrogel with High Stiffness Induced by 310‐Helices to β‐Sheet Transition in Water
Tabular Data - 36.2 KB - 24 Variables, 168 Observations - UNF:6:Xug7V412jZaPtd3iXPOVqA==
FTIR_curvefitting_assignment |
May 26, 2020 -
A Short Peptide Hydrogel with High Stiffness Induced by 310‐Helices to β‐Sheet Transition in Water
Unknown - 2.0 MB -
MD5: bef6d2fc542ac5f8c153fd6a3e7311ef
Rheology data |
May 26, 2020
Research topics: • Research data management • Open Access • Data repository |
May 12, 2020 - Lim Zhi Wei
Lim, Zhi Wei; Vijaykumar B. Varma; R. V. Ramanujan; Ali Miserez, 2020, "Replication data for: Magnetically responsive peptide coacervates for dual hyperthermia and chemotherapy treatments of liver cancer", https://doi.org/10.21979/N9/Y7CAS3, DR-NTU (Data), V1, UNF:6:CgWydUb+URiN2s1BBJxPHw== [fileUNF]
Liver cancer is an aggressive malignancy associated with high levels of mortality and morbidity. Doxorubicin (Dox) is often used to slow down liver cancer progression; however its efficacy is limited, and its severe side effects prevent its routine use at therapeutic concentratio... |
